摘要
考虑到大脑和周边组织的病理生理学变化,阿尔茨海默病作为一种系统病理学疾病的出现改变了研究规范以便更好的了解该疾病的分子基础。在目前研究中,我们评估了病程进展对3、6和12个月龄的三转基因老年痴呆小鼠模型及相对应年龄的非转基因小鼠的骨骼肌生理相关特征的影响。我们的结果表明3个月龄的3xTg-AD小鼠的骨骼肌功能已经受到影响,由乙酰胆碱酯酶和过氧化氢酶活性的缺乏及线粒体膜脂肪酸组分的变化得到证明。此外,3xTg-AD小鼠骨骼肌中的β1-40 淀粉样蛋白随着年龄增长积累增加,这种影响发生于线粒体生物学功能障碍之前,并且仅12月龄小鼠出现这种状况,以呼吸控制率和ADP/O 指数减少及复合酶体I活性降低为特征。与年龄相一致的非转基因小鼠相比,HPLC-MS/MS 分析法表明12月龄的3xTg-AD小鼠骨骼肌中的磷脂组分发生了明显变化。在3xTg-AD小鼠中发现溶血卵磷脂水平的增加与含有花生四烯酸卵磷脂的分子种类减少相关,显示磷脂酶A2活性及骨骼肌炎症增强。另外与年龄相一致的非转基因小鼠相比,观察到3xTg-AD小鼠中缩醛磷脂酰乙醇胺含量减少及磷脂酰肌醇水平的增加。总之,这些观察数据提示3xTg-AD 小鼠骨骼肌更易于发生氧化及炎症反应。
关键词: 阿尔茨海默病,β淀粉样,脂类组学,线粒体生物学功能,磷脂酶A2,磷脂质,骨骼肌
Current Alzheimer Research
Title:Age-Dependent Biochemical Dysfunction in Skeletal Muscle of Triple- Transgenic Mouse Model of Alzheimer`s Disease
Volume: 12 Issue: 2
Author(s): Vera F. Monteiro-Cardoso, Marisa Castro, M.M. Oliveira, Paula I. Moreira, Francisco Peixoto and Romeu A. Videira
Affiliation:
关键词: 阿尔茨海默病,β淀粉样,脂类组学,线粒体生物学功能,磷脂酶A2,磷脂质,骨骼肌
摘要: The emergence of Alzheimer`s disease as a systemic pathology shifted the research paradigm toward a better understanding of the molecular basis of the disease considering the pathophysiological changes in both brain and peripheral tissues. In the present study, we evaluated the impact of disease progression on physiological relevant features of skeletal muscle obtained from 3, 6 and 12 month-old 3xTg-AD mice, a model of Alzheimer`s disease, and respective agematched nonTg mice. Our results showed that skeletal muscle functionality is already affected in 3-month-old 3xTg-AD mice as evidenced by deficient acetylcholinesterase and catalase activities as well as by alterations in fatty acid composition of mitochondrial membranes. Additionally, an age-dependent accumulation of amyloid-β1-40 peptide occurred in skeletal muscle of 3xTg-AD mice, an effect that preceded bioenergetics mitochondrial dysfunction, which was only detected at 12 months of age, characterized by decreased respiratory control ratio and ADP/O index and by an impairment of complex I activity. HPLC-MS/MS analyses revealed significant changes in phospholipid composition of skeletal muscle tissues from 3xTg-AD mice with 12 months of age when compared with age-matched nonTg mice. Increased levels of lyso-phosphatidylcholine associated with a decrease of phosphatidylcholine molecular species containing arachidonic acid were detected in 3xTg-AD mice, indicating an enhancement of phospholipase A2 activity and skeletal muscle inflammation. Additionally, a decrease of phosphatidylethanolamine plasmalogens content and an increase in phosphatidylinositol levels was observed in 3xTg-AD mice when compared with age-matched nonTg mice. Altogether, these observations suggest that the skeletal muscle of 3xTg-AD mice are more prone to oxidative and inflammatory events.
Export Options
About this article
Cite this article as:
Vera F. Monteiro-Cardoso, Marisa Castro, M.M. Oliveira, Paula I. Moreira, Francisco Peixoto and Romeu A. Videira , Age-Dependent Biochemical Dysfunction in Skeletal Muscle of Triple- Transgenic Mouse Model of Alzheimer`s Disease, Current Alzheimer Research 2015; 12 (2) . https://dx.doi.org/10.2174/1567205012666150204124852
DOI https://dx.doi.org/10.2174/1567205012666150204124852 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections:
Recent Patents on Regenerative Medicine The Evolution of Schizophrenia: A Model for Selection by Infection, with a Focus on NAD
Current Pharmaceutical Design Quinoline: An Attractive Scaffold in Drug Design
Mini-Reviews in Medicinal Chemistry Dysfunction of Endoplasmic Reticulum (ER) and Mitochondria (MT) in Alzheimer's Disease: The Role of the ER-MT Cross-Talk
Current Alzheimer Research Safety of Dipeptidyl Peptidase 4 Inhibitors for Treatment of Type 2 Diabetes
Current Drug Safety Transcriptomics Study of Neurodegenerative Disease: Emphasis on Synaptic Dysfunction Mechanism in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Non Smoking for Successful Aging: Therapeutic Perspectives
Current Pharmaceutical Design Emerging Anticoagulant Therapies for Atrial Fibrillation: New Options, New Challenges
Current Medicinal Chemistry Intranasal Lipid Particulate Drug Delivery Systems: An Update on Clinical Challenges and Biodistribution Studies of Cerebroactive Drugs in Alzheimer’s disease
Current Pharmaceutical Design Clinical, Immunological and Therapeutic Aspects of Autoimmune Encephalitis
Recent Patents on CNS Drug Discovery (Discontinued) Oxidative Stress and Antioxidants in Neurological Diseases: Is There Still Hope?
Current Drug Targets Compensating, Controlling, Resigning and Accepting-Older Persons Perception of Physical Decline
Current Aging Science Use of STAT1 Inhibitors in the Treatment of Brain I/R Injury and Neurodegenerative Diseases
Central Nervous System Agents in Medicinal Chemistry Mild Cognitive Impairment: Advantages of a Comprehensive Neuropsychological Assessment
Current Alzheimer Research The APOE Genotype: Modification of Therapeutic Responses in Alzheimer's Disease
Current Pharmaceutical Design Heterologous Production of Death Ligands’ and Death Receptors’ Extracellular Domains: Structural Features and Efficient Systems
Protein & Peptide Letters MicroRNAs and Stem Cells to the Rescue
Current Neurovascular Research Vitamin D and Infectious Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets HIV-1 Proteins, Tat and gp120, Target the Developing Dopamine System
Current HIV Research Polymer-Based Drug Delivery Devices for Neurological Disorders
CNS & Neurological Disorders - Drug Targets